Hennion & Walsh Asset Management, Inc. Day One Biopharmaceuticals, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.35 Billion
- Q2 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 96,821 shares of DAWN stock, worth $561,561. This represents 0.03% of its overall portfolio holdings.
Number of Shares
96,821
Previous 137,968
29.82%
Holding current value
$561,561
Previous $1.11 Million
43.49%
% of portfolio
0.03%
Previous 0.05%
Shares
9 transactions
Others Institutions Holding DAWN
# of Institutions
197Shares Held
77MCall Options Held
138KPut Options Held
208K-
Atlas Venture Life Science Advisors, LLC6.43MShares$37.3 Million14.93% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$34.5 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$33.4 Million0.95% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$26.3 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL4.06MShares$23.5 Million0.14% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $426M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...